ArticleJournal of thrombosis and thrombolysis2020

Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome.

Ying X Gue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.